Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer

Not Recruiting

Trial ID: NCT00547144


To determine the safety, feasibility and appropriate dendritic cell dose to vaccinate patients with pancreas cancer

Official Title

A Phase I/II Trial of Intratumoral Dendritic Cell Immunotherapy in Combination With Gemcitabine and Stereotactic Radiosurgery in Unresectable Pancreatic Cancer

Stanford Investigator(s)

George A. Fisher Jr.
George A. Fisher Jr.

Colleen Haas Chair in the School of Medicine

Yasodha Natkunam, M.D., Ph.D
Yasodha Natkunam, M.D., Ph.D

Ronald F. Dorfman, MBBch, FRCPath Professor of Hematopathology


Inclusion Criteria:1. Patients must have histologically or cytologically confirmed
adenocarcinoma of the pancreas. The site of the primary lesion should be confirmed
endoscopically, radiologically, or surgically to be in the pancreas.

2. Patients must be deemed unresectable due to involvement of critical vasculature,
adjacent organ invasion, presence of metastasis, or other medical condition making surgical
resection unfavorable.

3. Patients must have a primary or metastatic lesion measurable in at least one dimension
by RECIST criteria within 4 weeks prior to entry of study 4. More than 4 weeks must have
elapsed from the time of major surgery or completion of the last dose of chemotherapy,
radiation therapy, investigational therapy and patients must adequately recover from these

5. Life expectancy of >3 months. 6. Karnofsky performance status >70%. 7. Patients must
have normal organ and marrow functions as defined below: absolute neutrophil count
>1,500/mm3 platelets >70,000/mm3 total bilirubin <1.5 mg/dL AST(SGOT)/ALT(SGPT) <2.5 X
institutional upper limit of normal creatinine within normal institutional limits OR
creatinine clearance >60mL/min/1.73 m2 for patients with creatinine levels above
institutional normal.

albumin > 2.8 mg/dL 8. Patients must have adequate clotting function (platelet > 70k;
INR<1.4; PTT<60).

9. Age >18 years. 10. The effects of DCs on the developing human fetus are unknown. For
this reason, women of child-bearing potential and men must agree to use adequate
contraception (hormonal or barrier method of birth control) prior to study entry and for
the duration of study participation. Should a woman become pregnant or suspect she is
pregnant while participating in this study, she should inform her treating physician

11. No history of autoimmune diseases. 12. Ability to understand the study protocol and a
willingness to sign a written informed consent document. Exclusion Criteria:1. Patients
receiving anticoagulation therapy.

2. Patients who have received prior gemcitabine or radiation therapy to the pancreatic bed
3. Patients receiving any other investigational agents. 4. Patients with known brain
metastases will be excluded because of their poor prognosis and because they often develop
progressive neurological dysfunction that would confound the evaluation of neurological and
other adverse effects.

5. Uncontrolled concurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situation that would limit compliance with study

6. Patients who test positive for Hepatitis B virus, Hepatitis C virus or HIV.


drug: Gemcitabine

procedure: Dendritic Cell Immunotherapy

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jenna Rogers

New Trial Alerts

Receive email alerts when trials open to patients.